Indivior (NASDAQ:INDV) Reaches New 52-Week High – Here’s What Happened

Indivior PLC (NASDAQ:INDV) shares reached a new 52-week high on Friday . The company traded as high as $15.58 and last traded at $16.09, with a volume of 2981689 shares changing hands. The stock had previously closed at $15.40.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Indivior from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st. Craig Hallum raised their price target on shares of Indivior from $15.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 30th. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $17.00.

Indivior Trading Up 4.4%

The firm’s fifty day simple moving average is $12.79 and its 200-day simple moving average is $11.27.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.19. The company had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. Indivior had a negative net margin of 4.02% and a negative return on equity of 97.29%. On average, sell-side analysts forecast that Indivior PLC will post 1.22 earnings per share for the current year.

Institutional Trading of Indivior

Several hedge funds have recently modified their holdings of the stock. Rathbones Group PLC increased its stake in shares of Indivior by 11.6% in the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company’s stock valued at $183,000 after acquiring an additional 1,483 shares in the last quarter. Two Sigma Investments LP increased its stake in shares of Indivior by 2.1% in the 4th quarter. Two Sigma Investments LP now owns 110,880 shares of the company’s stock valued at $1,378,000 after acquiring an additional 2,237 shares in the last quarter. Stifel Financial Corp increased its stake in shares of Indivior by 24.0% in the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company’s stock valued at $158,000 after acquiring an additional 2,450 shares in the last quarter. PDT Partners LLC increased its stake in shares of Indivior by 4.7% in the 4th quarter. PDT Partners LLC now owns 57,520 shares of the company’s stock valued at $715,000 after acquiring an additional 2,596 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Indivior in the 4th quarter valued at $36,000. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.